Cookies disclaimer

I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.


The Management Board

Krzysztof Kaczmarczyk – President of the Management Board

A graduate of the Warsaw School of Economics with a specialization in finance and accounting and a former student of the University of Warsaw, majoring in International Relations. In 1999-2008, he worked for Deutsche Bank in Poland, where he held the position of Deputy Director of the Equity Market Analysis Department and Stock Market Analyst - Central and Eastern Europe Region. In 2008-2010, he held managerial positions in TP S.A. Group, including the position of Director of Strategy and Development Division. In 2010-2011, he worked for the Swiss investment bank Credit Suisse. In 2012-2015, he served as Vice President of the Management Board for Strategy and Development in Emitel - a terrestrial radio and television network operator in Poland. In 2016-2018, advisor to the Management Board of KGHM Polska Miedź S.A. Currently, professionally, since 2015, an independent member of Supervisory Boards of companies listed on the Warsaw Stock Exchange. He gained almost 15 years of supervisory experience sitting on over 30 supervisory boards of companies listed on the Warsaw Stock Exchange and non-public companies, including: Action, Alta, Arteria, Braster, BEST, BSC Drukarnia, Celon Pharma, Duon, Emitel, TP Edukacja i Wypoczynek, Warsaw Stock Exchange, Graal, Integer, InPost, KGHM Polska Miedź, KGHM International, KGHM TFI, LC Corp, Mabion, Magellan, Polimex-Mostostal, Polish Energy Partners, Robyg, SARE, TIM, Vigo System, Wirtualna Polska, Work Service, 4fun Media.


Sławomir Jaros, PhD, Eng Member of the Board

He graduated from the Warsaw University of Life Sciences with a major in biotechnology. He obtained his PhD in biology at the Polish Academy of Sciences in Warsaw. He completed the Polish-American Executive MBA Studies conducted jointly by the University of Maryland and the University of Lodz.

He engaged in many biotech projects – including the creation of recombinant proteins and vaccines. Sławomir Jaros has been associated with Mabion since late 2007 and his responsibilities include the development of technology and Mabion products. 

In 2015, Sławomir Jaros was chosen as one of the 10 best among the youngest members of management boards in big companies listed at the Warsaw Stock Exchange.


Grzegorz Grabowicz  – Member of the Board

Grzegorz Grabowicz graduated from the University of Lodz, at The Department of Management and Marketing, on the Accounting specialization, obtaining a Master's Degree in Management and Marketing. He completed the program organized by Nottingham Trent University and WSB at the Poznań University and he gained the title of EMBA (Executive Master of Business Administration in 2010). Grzegorz Grabowicz possesses full powers of the Statutory Auditor additionally.
Grzegorz Grabowicz gained his background and experience in management, working in Deloitte, Magellan S.A. and MEDFinance S.A. He was also a member of the Supervisory Board of Skarbiec Holding S.A. He is a member of the Supervisory Boards of Develia S.A. and X-Trade Brokers Dom Maklerski S.A.

Adam Pietruszkiewicz  – Member of the Board

Adam Pietruszkiewicz is a Partner at TWITI Investments. Adam’s key role at Twiti Investments consists in executing M&A transactions, fundraising and overview of portfolio companies. Adam joined Twiti Investments in December 2019. In total, Adam has 22 years of experience in the area of private equity, focusing on M&A transactions; also, he has developed an extensive network in the business community in CEE, especially in Poland. In 2016-2019 - Managing Director of COAST2COAST CAPITAL, 2016-2019 - Chairman of the Supervisory Board of Krosno Glass Sp. z o.o., 2014-2015 - Partner of ICENTIS Capital, 2001-2014 - Director at The Riverside Company. In 1998 Adam received Bachelor of Arts degree in Business Administration from Boston University, where he concentrated on International Management and International Relations.

The Supervisory Board of Mabion S.A.:

Robert Koński – Chairman of the Supervisory Board, Independent Member of the Supervisory Board

Graduate of the John F. Kennedy School of Government (MPA), Harvard University and Tufts University (BA) in the United States. Since March 2020 CEO and shareholder of  consulting company named Five Rand sp. z o. o. In recent years he worked, among others, for PGE Polska Grupa Energetyczna SA, Kulczyk Holding S.A., Euronet Worldwide, Inc. and Horton International. Between years 1990 and 1995, he was a member of the advisory team of the Minister of Finance (from Leszek Balcerowicz to Grzegorz Kołodka) in the process of transformation and restructuring the Polish financial services sector. He was also a member of the negotiating team with the London Club. Currently he is a member of the Supervisory Board of Platige Image S.A.  He meets the independence criteria referred to in principle 2.3 of the document "Best Practices of Companies Listed on the WSE 2021".

Józef Banach – Independent Member of the Supervisory Board

A graduate of the Law Faculty of the Jagiellonian University in Krakow. Legal Counsel. Managing Partner at InCorpore Banach Szczypiński Partners. He started his career at the Ministry of Finance, and then worked for several years at the PricewaterhouseCoopers sp. z.o.o., most recently as a leader of the Proceedings and International Tax Law team. Member of a number of supervisory boards of capital companies, including Chairman of the Supervisory Board of Poczta Polska SA and PHN SA. A long-time expert of the Tax Council at the PKPP Lewiatan, and  inter alias the deputy of the head of the Tax Council. Author of numerous publications in the field of law, including the commentary "Polish agreements on avoiding double taxation" CH Beck. Multiple representative of the parties in proceedings before administrative authorities and administrative and general courts ending with client's success. He meets the independence criteria referred to in principle 2.3 of the document "Best Practices of Companies Listed on the WSE 2021".

David John James – Independent Member of the Supervisory Board

A graduate of the University of Cambridge, certified auditor at the National Chamber of Statutory Auditors and ICAEW (Institute of Chartered Accountants in England and Wales). Currently International Liaison Partner, Grupa Strategia, Poland. He has 28 years of experience in audit and internal control. Member of the management boards of many companies, and start-up advisor in the CEE region for nearly fifty enterprises. Partner responsible for auditing the financial statements of over 100 enterprises and groups of companies from many sectors, both listed companies, private equity funds , as well as family businesses. His portfolio includes over 80 due diligence analyses, he has carried out financial audits of statutory activities, internal and forensic audits, and provided business advisory services to numerous clients. He has worked in Poland, UK, Germany, Czech Republic, Slovakia and Russia. He is fluent in eight languages and speaks twelve others. David James spent four years mentoring about 100 teams of young entrepreneurs participating in the Cambridge Python Project. As part of the project, organised under the aegis of the Embassy of the United Kingdom and the University of Cambridge, he trained students from all over Poland in modern business planning and budgeting. David James is the author of an original method of foreign language learning. He meets the independence criteria referred to in principle 2.3 of the document "Best Practices of Companies Listed on the WSE 2021".

Wojciech Wośko – Member of the Supervisory Board

A graduate of the Faculty of Medicine of the Medical Academy in Łódź and postgraduate studies in Management Accounting at the University of Łódź. Licensed securities broker (license No. 449). He has been associated with the capital market since 1994. He worked for HSBC Securities Polska, Dom Maklerski BZ WBK, Santander Biuro Maklerskie, where he was responsible for sales to institutional clients (investment funds, pension funds, asset management companies). He is competent in conducting transactions on domestic and foreign spot and derivativemarkets. He took part in the preparation and implementation of numerous offers of public companies on the primary and secondary market. He has been associated with Polfarmex S.A. since July 2020.

Sławomir Kościak – Independent  Member of the Supervisory Board

Licensed Investment Advisor with license number 303 and holder of the CFA (Chartered Financial Analyst_title. Graduated from the Warsaw School of Economics with a major in Finance and Banking, also studied at Aarhus School of Business in Denmark and Universität zu Köln in Germany, completed the Community of European Management Schools -Master's in International Management )CEMS MIM_management programme. Holder of a Educational Enterprise Foundation scholarship. He taught courses for stockbrokers (ZmiD and investment advisors) PERK. He has more than 10 years of experience in asset management. He worked, among others, at the European Investment Fund in Luxembourg and the Morgan Stanley real estate fund in Frankfurt. Between 2009 and 2020, he managed a number of different funds and investment strategies within TFI PZU, both with PZU Group's own funds and those entrusted by external clients, and equity, mixed, and absolute return funds. The investment portfolio included companies listed on the WSE as well as those listed on stock exchanges in the EU and the USA. Member of the investment committee, AUM of over PLN 20 billion. Since 2014, in the position of Medical Sector Director in TFI PZU, responsible for investments in companies from the health care sector.Mr. Sławomir Kościak meets the independence criteria referred to in principle 2.3 of "Good Practices of Companies Listed onthe WSE 2021".

Zofia Szewczuk – Independent  Member of the Supervisory Board

Ms. Zofia Szewczuk graduated from ESCP-EAP Europe and Poznań University of Economics and Business as Master of Science in Finance and Accounting for Business and Master of Management.She has more than 12 years of experience in the private equity industry, gained while working in leading funds in Poland and abroad. Since 2016, she has been associated with PFR S.A. where she currently holds the position of Office Director in the Investment Department of PFR S.A. and President of PFR Life Science Sp. z o.o.,a company specialising in investments in the field of biotechnology and health. Her previous experience includes the Mid Europa fund (2011-2015) and 3i fund (2009-2011). During this time, she had the privilege to participate in many transactions in sectors such as new technologies, services, manufacturing, health, and tourism. Ms. Zofia Szewczuk has extensive ownership and supervisory experience in representing the investor side. Her engagement involves regular cooperation with the management boards of companies in the implementation of development and recovery initiatives and performance monitoring. She currently serves on the supervisory board of PKL S.A. and is an observer at HCP. Ms. Zofia Szewczuk meets the independence criteria referred to in principle 2.3 of "Good Practices of Companies Listed onthe WSE 2021".


Division of responsibility of Members of the Management Board of Mabion S.A.:

Krzysztof Kaczmarczyk- President of the Management Board
He supervises the work of the Management Board and coordinates the work of other board members. The main tasks of the President of the Management Board are the development of the Company's strategy and investment policy as well as obtaining business and strategic partners for the Company. The President of the Management Board is also responsible for risk management, the scope of information obligations and investor relations as well as supervision over the correctness of the Company's operational and financial activities, and also for the implementation of its innovation policy.

Sławomir Jaros - Member of the Management Board
He is responsible for overseeing and managing the research and development area, including design of drugs, technology and analytics development, clinical trials and safe working practice field as well as pharmaceutical risk control. The Member of the Board’s responsibilities include collaboration with external partners in the technological, scientific and commercial areas and working out a strategy for the development of new products and technologies. He is also accountable for the area of manufacturing, control and quality assurance as well as for the implementation of technological and analytical processes into the pharmaceutical environment, expanding the scale of processes and quality, time and cost optimization.

Grzegorz Grabowicz - Member of the Management Board
He is responsible for overseeing and managing the Company's financial policy. He is accountable for acquiring financing, also for negotiating of significant financial operations and commercial transactions of the Company as well as creating financial plans of the Company and its financial reporting.

Adam Pietruszkiewicz - Member of the Management Board
He is responsible for the cooperation with Novavax, Inc. (leading the antigen project for the vaccine candidate) and new strategic and development projects of the Company.


Data on the shareholding structure of the Issuer and its shareholders holding at least 5% of votes at the General Meeting:


The Company’s share capital amounts to PLN 1,616,132.60 and is divided into 16,161,326 shares with a nominal value of PLN 0.10 each, including:

  • 450,000 series A, preferred, registered
  • 450,000 series B, preferred, registered
  • 450,000 series C, preferred, registered
  • 450,000 series D, ordinary bearer shares
  • 100,000 series E, preferred, registered
  • 100,000 series F, preferred, registered
  • 20,000 series G, preferred, registered
  • 2,980,000 series H, ordinary bearer shares
  • 1,900,000 series I ordinary bearer shares
  • 2,600,000 series J ordinary bearer shares
  • 790,000 series K ordinary bearer shares
  • 510,000 series L ordinary bearer shares
  • 360,000 series M ordinary bearer shares
  • 340,000 series N ordinary bearer shares
  • 340,000  series O ordinary bearer shares
  • 1.920.772 series P ordinary bearer share
  • 10.000 series S ordinary bearer share
  • 2,430,554 U series ordinary bearer shares

Registered shares of the A, B, C, E, F and G series are privileged in such a way that each of them entitles to two votes at the General Meeting. The total number of votes resulting from all issued shares is 17,731,326.



Listing of the shares of the Company at the Stock Exchange in Warsaw (GPW)


Divident policy

In the last 5 financial years the Company did not pay out dividends. The Management Board of the Company adopts the current dividend policy to the Company’s economic situation, taking into account the scope of necessary investments. At present the Company is in the development stage and it seems expedient to retain the possible profit in the Company.

Current rate


The primary goal of Mabion is to develop, manufacture and market oncology drugs which are biosimilar to the original biotechnology drugs already present on the market (so called reference drugs). Currently, the Company’s priority is to launch MabionCD20 onto as many international markets as possible. The Company intends to carry out the marketing authorisation process on its own, under a centralised procedure for the whole European Union where the system of registration for biosimilars is well-regulated. Moreover, one of the Company’s objectives is to launch drugs onto the American market. When it comes to regions with a less regulated system of marketing authorisation, such as African and Asian countries, Mabion plans to carry out both the sales and the whole authorisation procedure through local leading pharmaceutical companies on the basis of distribution agreements. The market of biotechnology drugs is already very attractive and its worth should increase significantly in the course of upcoming years. The strategy adopted by Mabion S.A. provides for the continuation of research and development pursuits in the field of new biotherapeutics. It's anticipated that the development strategy will be financed mainly by the Company’s own funds, as well as grants from the EU and national funds.

The Company annually updates the development plan for medicinal products, and may change it from time to time.

In 2019, following a review and update of the medicines development strategy, the catalogue of projects which the Company, currently or in the future, on its own or with partners, is interested in implementing, was changed. The Company classified scientific and research projects in three groups of projects, i.e. active projects, new projects which were to be launched in 2019, and partner projects. Currently the adopted development strategy was maintained.

Active projects
This is a group of projects of the greatest importance for the Company, as part of which the Company carries out work and invests funds. The group includes projects currently under way: MabionCD20, MabionMS and MabionEGFR.
Projects launched in 2019
The projects for which the Company started research and development work in 2019 are three biosimilar drugs in the area of autoimmunity, metabolic diseases and oncology (denosumab and omalizumab antibodies). At present, a significant part of the team responsible for the development of the aforementioned antibodies has been assigned to support the Company's priority projects (MabionCD20 and Novavax), in connection with the need to carry out work related to the development and optimisation of the process, as well as analytical and manufacturing work.
Partnership projects
These are the projects for which the Company considers starting implementation in the mid or long term, preferably in cooperation with a partner. The projects will concern, inter alia, autoimmune and oncological, or rare diseases.
As part of the partnership projects, the Company has undertaken the following activities:
  • Signing of a Memorandum of Understanding with Taxon Therapeutics Ltd. regarding cooperation in the research, development, and commercialisation of MabionCD20 antibody drug in specific clinical indications in the area of rare diseases (October 2020);
  • Entering into a framework agreement together with the first order for contractual services with Novavax, Inc. under which the Company, with Novavax’s participation, will undertake activities related to the transfer of the manufacturing process technology and antigen analytics of the vaccine candidate for COVID-19 under the working name of NVX-CoV2373 and will carry out technical trial runs of the process on a commercial scale at the Company’s facility (March 2021).



Corporate Documents


© Mabion S.A. all rights reserved Polityka Prywatności